# Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

> **NCT01885260** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 77 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** ISIS-GCGRRx - Dose Level 1
- **DRUG:** ISIS-GCGRRx - Dose Level 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01885260
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-11
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2016-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01885260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01885260, "Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01885260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*